Wellington Shields Capital Management LLC Sells 950 Shares of CVS Health Co. (NYSE:CVS)

Wellington Shields Capital Management LLC lowered its position in shares of CVS Health Co. (NYSE:CVS) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,503 shares of the pharmacy operator’s stock after selling 950 shares during the quarter. Wellington Shields Capital Management LLC’s holdings in CVS Health were worth $427,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Versor Investments LP acquired a new position in shares of CVS Health in the 3rd quarter valued at approximately $371,000. GSA Capital Partners LLP acquired a new stake in CVS Health in the 3rd quarter valued at approximately $816,000. Aptus Capital Advisors LLC lifted its stake in CVS Health by 7.7% in the 3rd quarter. Aptus Capital Advisors LLC now owns 12,078 shares of the pharmacy operator’s stock valued at $759,000 after acquiring an additional 865 shares in the last quarter. MQS Management LLC acquired a new position in CVS Health during the 3rd quarter worth approximately $237,000. Finally, Oppenheimer & Co. Inc. grew its stake in shares of CVS Health by 5.6% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 99,848 shares of the pharmacy operator’s stock worth $6,278,000 after acquiring an additional 5,325 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 0.2 %

CVS Health stock opened at $65.63 on Friday. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75. The stock has a market cap of $82.75 billion, a P/E ratio of 17.93, a P/E/G ratio of 0.98 and a beta of 0.53. The company’s 50-day moving average price is $58.47 and its two-hundred day moving average price is $57.00. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date was Thursday, January 23rd. CVS Health’s dividend payout ratio is 72.68%.

Analysts Set New Price Targets

A number of analysts have recently commented on CVS shares. Evercore ISI boosted their price objective on shares of CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Barclays raised their price objective on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Argus set a $77.00 target price on CVS Health in a report on Tuesday, February 18th. Finally, Truist Financial boosted their price target on CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $69.83.

Insiders Place Their Bets

In related news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.